等待开盘 05-18 09:30:00 美东时间
0.000
0.00%
Decoy Therapeutics (NASDAQ:DCOY) reported quarterly losses of $(4.18) per share which missed the analyst consensus estimate of $(4.08) by 2.45 percent. This is a 98.26 percent increase over losses of $(240.07) per share
05-09 06:16
CBO Peter Marschel to Lead HubXchange Roundtable on Computational Peptide Design CSO Dr. Barbara Hibner and CTO Dr. Michael Lipp to Co-Present at Peptide-Based Therapeutics Summit; Advisor D...
04-27 20:45
Decoy Therapeutics to present at virtual investor Closing Bell event Decoy Therapeutics to participate in Virtual Investor Closing Bell webcast on April 9, 2026 at 4:00 p.m. ET. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT
04-09 20:36
Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), announces that on March 31, 2026 the Company received notification from the Nasdaq Stock Market LLC that it has regained compliance with Listing Rule
04-02 21:05
Decoy Therapeutics shares are trading lower after the company announced a 1-for...
03-06 01:25
Decoy Therapeutics Inc. (NASDAQ:DCOY), a preclinical-stage biopharmaceutical company that is engineering the next generation of peptide conjugate therapeutics, today announced that it will effect a 1-for-12 reverse stock
03-05 21:39
CAMBRIDGE, Mass., March 5, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (NASDAQ: DCOY), a preclinical-stage biopharmaceutical company that is engineering the next generation of peptide conju...
03-05 21:30
- Connect with the Company on Webull here CAMBRIDGE, Mass. and HOUSTON, Feb. 11, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a preclinical biopharm...
02-11 22:00
今日重点评级关注:RBC Capital:维持Compass Pathways"跑赢大市"评级,目标价从16美元升至21美元;RBC Capital:维持GH Research"跑赢大市"评级,目标价从33美元升至40美元
01-26 14:32
Ladenburg Thalmann analyst Kevin DeGeeter initiates coverage on Decoy Therapeutics (NASDAQ:DCOY) with a Buy rating and announces Price Target of $2.5.
01-23 20:29